|
pubmed:abstractText |
There is growing clinical interest in thalidomide for the treatment of various disorders due to its anti-inflammatory, immunomodulatory, and anti-angiogenic properties. In numerous clinical trials thalidomide is used as an adjunct to standard therapy. Therefore, clinicians should be aware of all possible drug-drug interactions that might occur with this drug. P-glycoprotein (P-gp), a drug efflux transporter that is expressed in many tissues, is the cause of several drug-drug interactions. P-gp induction or inhibition can lead to ineffective therapy or side-effects. In this study, we investigated thalidomide's potential to cause drug-drug interactions on the level of P-gp.
|
|
pubmed:affiliation |
Department of Clinical Pharmacology and Toxicology Petersgraben, University Hospital Basel and Department of Pharmaceutical Sciences, Petersgraben 4, CH-4031, Basel, Switzerland.
|
